Trinity Biotech (NASDAQ:TRIB) Earns Buy Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report released on Thursday. The brokerage issued a buy rating on the stock.

Trinity Biotech Trading Up 2.4 %

Shares of TRIB opened at $2.13 on Thursday. The firm has a market capitalization of $16.23 million, a P/E ratio of -0.76 and a beta of 1.16. Trinity Biotech has a 12-month low of $1.49 and a 12-month high of $5.50. The firm has a fifty day moving average price of $1.96 and a 200-day moving average price of $2.15.

Trinity Biotech (NASDAQ:TRIB) last issued its earnings results on Thursday, May 23rd. The company reported ($0.37) EPS for the quarter. Analysts predict that Trinity Biotech will post -2.17 earnings per share for the current year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.